CapsoVision (CV) Preferred Stock Liabilities (2024 - 2025)
CapsoVision's (CV) quarterly Preferred Stock Liabilities came in at $143.6 million in Q2 2025, up 11.66% year-over-year from $128.6 million in Q2 2024, and little changed quarter-over-quarter from $143.6 million in Q4 2024.
Analysis
CapsoVision (CV) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends
CapsoVision has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $143.6 million for Q2 2025.
- In Q2 2025, Preferred Stock Liabilities rose 11.66% year-over-year to $143.6 million; the TTM figure through Jun 2025 stood at $143.6 million (up 11.66% YoY), while the FY2024 annual figure was $143.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $143.6 million for Q2 2025 at CapsoVision, roughly flat from $143.6 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $143.6 million in Q4 2024 to a low of $128.6 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | GE HealthCare Technologies | 31.10 Bn | 29.22 Bn | 2.18 Bn | - |
| 2 | Lantheus Holdings | 6.59 Bn | 6.00 Bn | 241.86 Mn | - |
| 3 | Heartflow | 4.24 Bn | 3.87 Bn | 53.19 Mn | - |
| 4 | Neogen | 2.58 Bn | 2.39 Bn | 107.80 Mn | - |
| 5 | Butterfly Network | 1.75 Bn | 1.62 Bn | 23.29 Mn | - |
| 6 | QuidelOrtho | 954.15 Mn | 830.75 Mn | - | - |
| 7 | Ceribell | 944.88 Mn | 815.62 Mn | 25.94 Mn | - |
| 8 | Anbio Biotechnology | 941.05 Mn | 929.15 Mn | - | - |
| 9 | Varex Imaging | 780.16 Mn | 694.86 Mn | 76.70 Mn | - |
| 10 | CapsoVision | 299.69 Mn | 290.62 Mn | 1.87 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 143.63 Mn |
| Dec 31, 2024 | 143.63 Mn |
| Sep 30, 2024 | 138.63 Mn |
| Jun 30, 2024 | 128.63 Mn |